AGENDA: Do not miss!!
We will celebrate the World TB Day
at Palau Macaya, Barcelona (thanks to the LaCaixa Foundation), on 22th March 2017, from 10 am to 3 pm.
Organized by the FUITB.
Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional tuberculosis treatment, complicated by emerging drug resistances. We have been working on Host-directed therapies, mainly in non-steroidal anti-inflammatory drugs (NSAIDs), since 2010. In collaboration with our colleagues from the … Continue reading
We spent last tweek in Tbilisi, Georgia, to prepare the start of our 2 new CT to evaluate hostdirected therapies: ibuprofen and the nutraceutical Nyaditum resae. A pilot CT will evaluate ibuprofen as coadjuvant treatment for Pre-XDR and XDR-TB; and … Continue reading
We are happy to announce that we are going to conduct a pilot clinical trial in the NCTLD in Tbilisi, Georgia to evaluate the potential benefit and safety of ibuprofen as coadjuvant in the treatment of XDR-TB cases. The study … Continue reading
The UTE has participated in a new article published in the Clinical Infectious Diseases journal, a new achievement of the The Host-Directed Therapies Network (HDT-NET). This new paper is leaded by Pr Zumla and Pr Maeurer, and explains why this consortium is needed, … Continue reading
The prestigious journal Nature Reviews Drug Discovery has published the The Host-Directed Therapies Network (HDT-NET) views and consensus as a comment article. The HDT-NET was founded last spring (April, 7th 2015) by Pr. Alimuddin Zumla and Pr. Markus Maeurer, and gathers 29 African … Continue reading